SRA's number for the day: 8
This article was originally published in SRA
Executive Summary
In the first half of 2013, the European Medicines Agency's scientific committee, the CHMP, recommended that eight new anticancer medicines be approved1,2.
You may also be interested in...
Dostarlimab, Zynteglo & COVID-19 Combo Drugs In The Spotlight At EMA
The sponsors of seven new drugs are set to find out this week whether the European Medicines Agency’s human medicines committee, the CHMP, will recommend pan-EU approval for their products. CHMP action is also expected regarding two potential combination therapies for COVID-19.
Lilly Undeterred By UK NICE Funding Blow For Second-Line Use Of Verzenios
Verzenios is one of three CDK4/6 inhibitors that are available via the Cancer Drugs Fund for use in previously treated patients with metastatic breast cancer, but it is the first for which health technology assessment body NICE has published a recommendation on routine commissioning.
EMA PRIME Wins For Bispecific Antibodies & Another Gene Therapy
Just three of the 13 applications that the European Medicines Agency most recently reviewed for entry onto its priority medicines scheme made the grade.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: